Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Reactogenicity of Boostrix in Healthy Vietnamese Children
NCT01988857Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2014
- Primary completion
- May 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) in diphtheria, Tetanus and pertussis, sponsored by GSK. Primary endpoints: Numbers of Subjects With Any and Grade 3 Solicited Local Symptoms at 4 days, Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms at 4 days and 2 more. Started Feb 2014; status: completed.
02
Drugs
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT01988857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01988857.